search
Back to results

Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture

Primary Purpose

Dupuytren Contracture, Dupuytren's Disease

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
No night splint
Sponsored by
Uppsala University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dupuytren Contracture focused on measuring Percutaneous needle fasciotomy, Splint

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18 years of age and older,
  • Palpable Dupuytren strand with passive extension deficit according to stadium 1 and 2 of the classification of Tubiana in one or two fingers excluding the thumb, defined as at least 30 degrees in the MCP joint and/or at least 20 degrees in the PIP joint and a maximum of 75 degrees in the MCP or PIP joint

Exclusion Criteria:

  • Multiple, invasive or wide strands in the palm,
  • Skin irritation,
  • Strand localization in the digit only,
  • Digital nerve injury,
  • Any former treatment for Dupuytren's contracture in the same digit,
  • Thumb contracture,
  • Stadium 3 and 4 according to the classification of Tubiana

Sites / Locations

  • Falu LasarettRecruiting
  • Akademiska SjukhusetRecruiting
  • Universitetssjukhuset ÖrebroRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Treatment with night splint after percutaneous needle fasciotomy

No treatment with night splint after percutaneous needle fasciotomy

Arm Description

Outcomes

Primary Outcome Measures

Reduction of finger joint contracture
Finger joint movement in order to extend the finger measured in degrees with a goniometer before and after treatment.

Secondary Outcome Measures

Change of active finger flexion
Finger joint movement in order to flex the finger measured in degrees with a goniometer before and after treatment.
Change of grip strength
The ability to grip with the hand measured with the Jamar hand dynamometer in kg before and after treatment.
Pain assessed by a numeric rating scale (NRS)
Report of pain in the treated finger using a numeric rating scale from 0 to 10, where 0 is equivalent to no pain at all and 10 is equivalent to the highest thinkable pain level.
Quality of life assessed by EQ-5D
Quality of life is measured by the EQ-5D questionnaire. This questionnaire is developed by the EuroQuol Group and measures 5 health dimensions: mobility, self care, usual activities, pain and discomfort, as well as anxiety and depression. The answers are transferred into an EQ-5D index from 0 to 1, where 0 is equivalent with the worst health state and 1 is equivalent with the best health state.
Dupuytren-disease-associated disability assessed by URAM
The URAM (Unité Rhumatologique des Affections de la Main) scale is a 9-item questionnaire for functional assessment in Dupuytren's disease with a range from 0-45 points, where 0 is equivalent with the best functional outcome and 45 is equivalent with the worst functional outcome.
Semmes-Weinstein monofilament test
Semmes-Weinstein monofilament test is a semi-quantitative test for sensory loss. Filaments in different sizes are used to put a different amount of pressure onto the skin. Depending on which filament size the patient is able to detect sensory loss can be investigated.
Study specific questionnaire concerning the patient's medical history
In this questionnaire the patient answers questions about present conditions such as diabetes and smoking, therapy with pain medication for the hand, how long the patient has been diagnosed with Dupuytren'd disease, if both hands are affected and if there is a positive family history.

Full Information

First Posted
February 28, 2022
Last Updated
February 10, 2023
Sponsor
Uppsala University
search

1. Study Identification

Unique Protocol Identification Number
NCT05300893
Brief Title
Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture
Official Title
Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture - a Randomised Controlled Multicenter Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 14, 2022 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
January 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Uppsala University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Dupuytren's contracture (DC) is associated with progressive finger flexion and extension deficit caused by fibrosis in the palm and digits. Treatment options include minimally invasive procedures such as percutaneous needle fasciotomy (PNF) and collagenase clostridium histolyticum injections as well as open fasciectomy. PNF has recently become more popular in Sweden because it is an office-based procedure which is relatively easy to perform without the usual risks and costs of open surgery. After treatment with PNF patients usually continue with supervised rehabilitation, which includes physical therapy and night splinting. Whether night splinting is beneficial in terms of reducing recurrence of DC is currently debated. This study aims to investigate whether night splinting after performed PNF helps to reduce recurrence rate or not. Patients who meet the inclusion criteria will be randomized into two groups: The first group will be treated as usual with physical therapy and night splinting after PNF. The second group will be treated with physical therapy without night splinting after PNF. Follow up includes physical examination regarding active range of motion, sensation and grip strength at procedure day and 2 weeks, 3, 12 and 36 months later as well as questionnaires regarding hand function, pain and quality of life at procedure day and 3, 12 and 36 months later. Patients who are randomized into the second group (no night splinting) will also be examined 3 weeks after PNF for observation in case of an early impairment regarding extension deficit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dupuytren Contracture, Dupuytren's Disease
Keywords
Percutaneous needle fasciotomy, Splint

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
154 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment with night splint after percutaneous needle fasciotomy
Arm Type
No Intervention
Arm Title
No treatment with night splint after percutaneous needle fasciotomy
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
No night splint
Intervention Description
Instead of the usual treatment with a night splint for three months after percutaneous needle fasciotomy patients do not receive treatment with a night splint.
Primary Outcome Measure Information:
Title
Reduction of finger joint contracture
Description
Finger joint movement in order to extend the finger measured in degrees with a goniometer before and after treatment.
Time Frame
at 1 year follow up
Secondary Outcome Measure Information:
Title
Change of active finger flexion
Description
Finger joint movement in order to flex the finger measured in degrees with a goniometer before and after treatment.
Time Frame
before and after treatment, at 2 weeks, 3, 12 and 36 months follow-up
Title
Change of grip strength
Description
The ability to grip with the hand measured with the Jamar hand dynamometer in kg before and after treatment.
Time Frame
before and after treatment, at 2 weeks, 3, 12 and 36 months follow-up
Title
Pain assessed by a numeric rating scale (NRS)
Description
Report of pain in the treated finger using a numeric rating scale from 0 to 10, where 0 is equivalent to no pain at all and 10 is equivalent to the highest thinkable pain level.
Time Frame
before treatment, at 3, 12 and 36 months follow-up
Title
Quality of life assessed by EQ-5D
Description
Quality of life is measured by the EQ-5D questionnaire. This questionnaire is developed by the EuroQuol Group and measures 5 health dimensions: mobility, self care, usual activities, pain and discomfort, as well as anxiety and depression. The answers are transferred into an EQ-5D index from 0 to 1, where 0 is equivalent with the worst health state and 1 is equivalent with the best health state.
Time Frame
before treatment, at 3, 12 and 36 months follow-up
Title
Dupuytren-disease-associated disability assessed by URAM
Description
The URAM (Unité Rhumatologique des Affections de la Main) scale is a 9-item questionnaire for functional assessment in Dupuytren's disease with a range from 0-45 points, where 0 is equivalent with the best functional outcome and 45 is equivalent with the worst functional outcome.
Time Frame
before treatment, at 3, 12 and 36 months follow-up
Title
Semmes-Weinstein monofilament test
Description
Semmes-Weinstein monofilament test is a semi-quantitative test for sensory loss. Filaments in different sizes are used to put a different amount of pressure onto the skin. Depending on which filament size the patient is able to detect sensory loss can be investigated.
Time Frame
before treatment, at 3, 12 and 36 months follow-up
Title
Study specific questionnaire concerning the patient's medical history
Description
In this questionnaire the patient answers questions about present conditions such as diabetes and smoking, therapy with pain medication for the hand, how long the patient has been diagnosed with Dupuytren'd disease, if both hands are affected and if there is a positive family history.
Time Frame
before treatment, at 3, 12 and 36 months follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18 years of age and older, Palpable Dupuytren strand with passive extension deficit according to stadium 1 and 2 of the classification of Tubiana in one or two fingers excluding the thumb, defined as at least 30 degrees in the MCP joint and/or at least 20 degrees in the PIP joint and a maximum of 75 degrees in the MCP or PIP joint Exclusion Criteria: Multiple, invasive or wide strands in the palm, Skin irritation, Strand localization in the digit only, Digital nerve injury, Any former treatment for Dupuytren's contracture in the same digit, Thumb contracture, Stadium 3 and 4 according to the classification of Tubiana
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniel Muder, MD
Phone
0046-23-490000
Email
daniel.muder@surgsci.uu.se
First Name & Middle Initial & Last Name or Official Title & Degree
Antje Straatmann, MD
Phone
0046-18-6110000
Email
antje.straatmann@akademiska.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephan Wilbrand, MD, PhD
Organizational Affiliation
Uppsala University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Falu Lasarett
City
Falun
State/Province
Dalarna
ZIP/Postal Code
79182
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Muder, MD
Phone
0046-23-490000
Email
daniel.muder@surgsci.uu.se
First Name & Middle Initial & Last Name & Degree
Anna-Karin Tibell, MD
Phone
0046-23-490000
Email
anna-karin.tibell@regiondalarna.se
Facility Name
Akademiska Sjukhuset
City
Uppsala
State/Province
Uppsala Län
ZIP/Postal Code
75185
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antje Straatmann, MD
Phone
0046-18-6110000
Email
antje.straatmann@akademiska.se
Facility Name
Universitetssjukhuset Örebro
City
Örebro
State/Province
Örebro Län
ZIP/Postal Code
70185
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Madeleine Harryson, MD
Phone
0046-19-6023656
Email
madeleine.harryson@regionorebrolan.se

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture

We'll reach out to this number within 24 hrs